Skip to main content
Cutia Therapeutics logo

Cutia Therapeutics — Investor Relations & Filings

Ticker · 2487 HKEX Manufacturing
Open in API
Filings indexed 176 across all filing types
Latest filing 2025-04-22 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2487

About Cutia Therapeutics

http://www.cutiatx.com

Cutia Therapeutics is an R&D-driven biopharmaceutical platform established in 2019, specializing in the research, development, manufacture, and commercialization of dermatological treatments. The company is dedicated to providing a comprehensive suite of innovative, safe, and effective solutions for patients and consumers. Its core therapeutic focus areas include the management of localized adipose accumulation and various scalp diseases. As a dermatology-focused entity, Cutia maintains a dedicated pipeline emphasizing novel candidates, including those targeting the Immune System domain.

Recent filings

Filing Released Lang Actions
(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES (3) PROPOSED RE-APPOINTMENT OF AUDITOR AND (4) NOTICE OF ANNUAL GENERA
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a shareholder circular issued by Cutia Therapeutics in connection with its Annual General Meeting. It contains the notice of meeting, resolutions for re-election of directors, share repurchase and issuance mandates, auditor re-appointment, explanatory statements, appendices, and proxy form instructions. This type of comprehensive proxy statement and solicitation of votes matches the definition of a Proxy Solicitation & Information Statement.
2025-04-22 English
2024 Environmental, Social and Governance Report
Environmental & Social Information Classification · 1% confidence The document is titled “2024 Environmental, Social & Governance Report” and systematically covers ESG topics such as governance structure, products quality and safety, employee practices, environmental management, and social engagement. It follows ESG reporting standards, includes performance indicators and an index for the HKEX ESG guide. This clearly identifies it as an Environmental & Social Information report.
2025-04-22 English
2024 Annual Report
Annual Report Classification · 1% confidence The document is explicitly titled 'Annual Report 2024' for Cutia Therapeutics. It contains comprehensive sections including the Chairman's Statement, Management Discussion and Analysis, Financial Highlights, and a detailed table of contents listing financial statements (Profit or Loss, Financial Position, Cash Flows, etc.). It is a full-year statutory report, not an announcement or a summary, and thus fits the definition of a 10-K (Annual Report). FY 2024
2025-04-22 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Regulatory Filings Classification · 1% confidence The document is a standardized HKEX Form FF301: a monthly return on equity issuers’ movements in share capital, share options, treasury shares and related confirmations under Listing Rule 19B. It is a routine regulatory filing to the exchange, not an investor presentation, earnings release, board change, or repurchase-specific notice. It does not itself present full financial statements (10-K/IR) nor announce a report’s publication. As it does not fit any of the more specific categories (e.g., share repurchase, M&A, dividends, etc.), it falls into the fallback “Regulatory Filings” category.
2025-04-03 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024” and contains audited consolidated annual results, key financial highlights, business highlights and MD&A. It is the initial announcement of the full-year financial results rather than the complete annual report (with full statutory statements and notes). Therefore, it matches the definition of an Earnings Release (ER) rather than a full Annual Report (10-K) or Report Publication Announcement (RPA). FY 2024
2025-03-24 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a short announcement disclosing the date of the Board meeting to consider and approve the annual results and declare any dividend. It does not contain the actual financial results or dividend amounts, nor does it change management or board composition. It simply notifies shareholders of the timing for report approval and publication. This fits the definition of a Report Publication Announcement (RPA).
2025-03-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.